GlassScriptPhysician profile
Binu J Kunjummen
NPI 1437331196
$8,642.57
in general payments reported to CMS, 2019-2025
41 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $476 · 2021: $431 · 2022: $2,514 · 2023: $851 · 2024: $843 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Travel and Lodging: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.90 |
| Travel and Lodging | $635.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,760.67 | 2022-2023 | Xience Skypoint |
| Janssen Pharmaceuticals, INC | $1,049.06 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $898.10 | 2019-2024 | Watchman Flx, Jetstream Sc |
| Surmodics, INC. | $791.95 | 2025 | Sublime Microcatheter, 018, 200cm, Straight, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Angiodynamics, INC. | $517.15 | 2022-2025 | Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Pfizer INC. | $440.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $392.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.38 | 2019-2025 | Farxiga |
| Amgen INC. | $279.92 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $224.13 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $140.68 | 2022-2025 | Opsumit, Uptravi |
| Reflow Medical INC | $133.55 | 2025 | |
| Veryan Medical Incorporated | $132.35 | 2025 | Biomimics 3d Vascular Stent System |
| Baxter Healthcare | $131.14 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Edwards Lifesciences Corporation | $115.22 | 2019-2025 | Sapien 3 Ultra Resilia |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binu Kunjummen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.